Letermovir Conversion for Cytomegalovirus Prophylaxis in Solid Organ Transplant
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70366 ↗At a glance
Journal article in Clinical Transplantation, 2025. Written by Suneri J Amin and 5 co-authors. Institution: Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA. Major MEDLINE topics: Cytomegalovirus Infections, Antiviral Agents, Organ Transplantation, Cytomegalovirus. Cited 1 times so far (Crossref); 14 references.
Abstract (original language)
Background
Cytomegalovirus (CMV) is a common opportunistic infection post‐solid organ transplant; however, traditional prophylaxis agents have been associated with myelosuppression, limiting their use. Letermovir (LTV) is an antiviral approved for use in kidney transplantation, and often used off‐label in non‐renal transplant patients; however, little data exist on cell count recovery and time to recovery in the non‐renal and multi‐organ transplant population.
Methods
This was a single‐center, retrospective, descriptive cohort study at a large academic medical center assessing conversion to LTV from (val)ganciclovir for primary CMV prophylaxis. Outcomes included change in white blood cell (WBC) count from immediately prior to LTV conversion to 30 days post‐initiation, indications for switching to LTV, and rates of breakthrough CMV infection.
Results
Fifty‐eight patients transplanted between January 1, 2017, and December 31, 2023, were included in this cohort, with the majority being lung transplant recipients (57%). Median increase in WBC was + 2.07 k/µL (IQR 3.95–8.21; p < 0.01) from time of LTV initiation to 30 days following conversion. The most common indication for LTV was pancytopenia in 26 patients (45%). Breakthrough CMV infections occurred in four patients (7%), all of which were viremia, and did not exhibit resistance against CMV active agents. There was an observed increase in mycophenolate use and tolerance and a decrease in granulocyte‐colony stimulating factor (G‐CSF) over the study period.
Conclusion
LTV was effective and well‐tolerated for primary CMV prophylaxis in an extra‐renal transplant population and may be a safe alternative in patients experiencing sustained hematologic toxicities with (val)ganciclovir across all transplant groups.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
- Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
- Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA.
- J.C. Walter Jr. Center for Transplantation, Houston Methodist Hospital, Houston, Texas, USA.
ORCID profiles: Suneri J Amin
Cite
APA
Amin, S. J., Rogers, A. W., Yun, A. N., Nigo, M., Ghobrial, R. M., & Gaber, A. O. (2025). Letermovir Conversion for Cytomegalovirus Prophylaxis in Solid Organ Transplant. Clinical Transplantation. https://doi.org/10.1111/ctr.70366
Vancouver
Amin SJ, Rogers AW, Yun AN, Nigo M, Ghobrial RM, Gaber AO. Letermovir Conversion for Cytomegalovirus Prophylaxis in Solid Organ Transplant. Clinical Transplantation. 2025. doi:10.1111/ctr.70366
BibTeX
@article{Amin2025,
author = {Amin, Suneri J and Rogers, Alex W and Yun, Allison N and Nigo, Masayuki and Ghobrial, R Mark and Gaber, A Osama},
title = {Letermovir Conversion for Cytomegalovirus Prophylaxis in Solid Organ Transplant},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70366}
}
EUVIMED